| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 22
| Issue : 4 | Page : 275-279 |
|
|
Cardiac myosin activation in the treatment of congestive heart failure: New therapeutic options and review of literature
Arroj Ali1, Ramy Abdelmaseih1, Ravi Thakker2, Mohammed Faluk1, Syed Mustajab Hasan1
1 College of Medicine, University of Central Florida, Orlando, Florida, USA
2 Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
Correspondence Address:
Dr. Arroj Ali
University of Central Florida, College of Medicine 6500 W Newberry Rd, Gainesville, FL 32605
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_39_21
|
|
|
Congestive heart failure (HF) remains a major cause of cardiac-related morbidity and mortality, despite major therapeutic advancements. A newer class of medications has recently been developed which targets the root cause of HF, which is reduced myocardial contractility. This article aims to highlight the cardiac myosin activator class of drugs and the trials to date highlighting their effects on HF outcomes.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
